- Executive Chairman to Continue to Fulfill Interim CEO Duties as Board Commences Executive Search - Data Correction for Fifth Patient in Phase 2 PNH Trial for …
[Read more...] about Akari Therapeutics Announces Resignation of CEO
Akari Therapeutics Announces Edison’s Withdrawal of Edison Report titled “Akari’s Coversin matches Soliris in Phase II”
NEW YORK and LONDON, April 27, 2017 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, clinical-stage biopharmaceutical company, released today a …
Akari Therapeutics Demonstrates Positive Response with Coversin in Ongoing Phase 2 PNH Trial and In Additional Clinical Targets
NEW YORK and LONDON, April 24, 2017 -Interim Phase 2 PNH data demonstrate positive response with Coversin™ -Phase 3 PNH program expected to commence in …
Akari Therapeutics to Present at the Jefferies Complement Symposium
NEW YORK and LONDON, April 3, 2017 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that Dr. …
[Read more...] about Akari Therapeutics to Present at the Jefferies Complement Symposium
Akari Therapeutics Announces FDA Fast Track Designation For Coversin
NEW YORK and LONDON, March 30th, 2017 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today that …
[Read more...] about Akari Therapeutics Announces FDA Fast Track Designation For Coversin
